Screens and eye strain

What Actually Helps Tired Eyes At A Screen

Eight hours of close work leaves most people with eyes that ache by six in the evening. The interventions with controlled evidence behind them are not the ones the category sells hardest, and two of them are free.

By Visivra Team at Visivraes · Medical review: Dr. Steven Christiansen, MD · Revised September 30, 2026 · Screens and eye strain

What is actually happening to a tired eye

Three things at once, and untangling them explains why the popular remedy misses.

The first is the focusing muscle. Reading at close range means the ciliary muscle holds a sustained contraction, and after hours of it the muscle does not fully relax between tasks. That residual tone is measurable and it is what a tired near-focus feels like from the inside.

The second is the tear film. The TFOS Lifestyle report on the digital environment is the most thorough review of this and its central observation is simple: blink rate falls during concentrated visual tasks, incomplete blinks increase, the tear film breaks up between blinks, and the surface of the eye dries. That is most of what people describe as strain.

The third is uncorrected refractive error. A prescription that is a year out of date makes the first two worse, because the focusing system compensates all day for something a lens should be doing.

The blue-light question, settled

It is worth dealing with this early, because it absorbs most of the attention in this space and it has been tested properly.

The Cochrane review of blue-light filtering spectacle lenses asked whether filtering blue light improves visual performance, reduces eye strain or protects macular health in adults. It found no evidence of a short-term benefit for eye strain, no clear effect on visual performance, and nothing either way on macular health.

That is a review of lenses rather than of capsules, and it is the closest evidence the proposition has. The underlying physical fact, that macular pigment absorbs short-wavelength light, is not in dispute. What does not follow from it is that reducing blue light produces an effect anyone can detect.

This matters for reading labels. A pack claiming to help defend the eyes from blue light exposure is making a structure and function statement about a filter property. It is not claiming a measured reduction in eye strain, and a reader who hears the second thing has heard more than was said. The claims page takes all four of this pack’s statements apart for exactly that reason.

What has controlled evidence behind it

Ordered by how much control the evidence had and how little the intervention costs, not by how heavily each one is marketed.

The blink-training trial is worth singling out because it is one of very few controlled results in this space. Screen users were prompted to blink properly by software, and both blink rate and dry eye symptoms improved against control. The intervention costs nothing and nobody sells it.

That is the shape of this whole field. The things with the best evidence are behavioural and optical, they are unglamorous, and there is no product attached to them.

Where a supplement fits, honestly

Not nowhere, and not first.

The ciliary-muscle trial gave 240 mg of standardised bilberry extract once a day for twelve weeks to 109 adults aged twenty to sixty and measured the tonic state of the ciliary muscle after a screen task. Post-load readings improved at weeks eight and twelve. That is a direct measurement of the first of the three mechanisms above.

The screen-worker trial used 480 mg of bilberry extract a day for eight weeks in office workers screened for low critical flicker fusion. Flicker fusion held up better after a screen load in the supplemented group and five subjective fatigue symptoms improved.

The 2025 astaxanthin trial used 4 mg of astaxanthin a day for eighty-four days, in children aged 10 to 14. Symptom scores improved by about twenty per cent more than placebo and a visual fatigue scale by twenty-seven. Its participants were children, which is a real limit on reading it across to an adult buyer.

All three are small. All three used stated amounts. None of them tested a finished multi-ingredient capsule, and a product naming bilberry without a figure cannot be lined up against any of them, which is the point the label page keeps returning to.

A fortnight of changes worth trying first

1. Book an eye test if it has been more than two years, or more than one if anything has changed. This is the highest-value item on the list by a distance.
2. Move the top of the screen to just below eye level, so the lids sit lower and less surface is exposed.
3. Turn down the overhead light and raise the ambient light behind the screen, so the contrast between the two falls.
4. Set a repeating reminder to look at something twenty feet away for twenty seconds, every twenty minutes.
5. Blink deliberately and completely at the end of each of those breaks. Incomplete blinks are the failure mode, not absent ones.
6. Only then consider a capsule, and give it the full window rather than a fortnight.

Why this category markets the weakest thing hardest

Worth a paragraph, because noticing the pattern makes the rest of the aisle easier to read.

Blink rate and screen position are free and nobody owns them. An up-to-date prescription is sold by an optician rather than by a supplement brand. Room lighting is a lamp. None of those has a margin attached, so none of them appears on a bottle.

Blue light, by contrast, is a physical phenomenon with a real absorption mechanism, a plausible-sounding explanation and a product attached at both ends: a lens and a capsule. It is marketable in a way that blinking is not, and that difference explains the volume of the messaging far better than the strength of the evidence does.

This is not an argument that the capsule does nothing. The bilberry and astaxanthin trials above are real, small, and at stated amounts. It is an argument for ordering the interventions by evidence rather than by how loudly each one is sold, which puts the capsule fourth or fifth rather than first.

A note on the founding trials

One more distinction is worth carrying out of this post. The trials that built the eye supplement shelf were about age-related macular degeneration in people who already had it. The trials about screens and eye fatigue are a separate, much smaller and much newer literature, and they measure different things in different people.

A label that carries both stories at once is not lying, but it is combining two evidence bases that do not overlap. The vision supplement guide separates them at length, and it is the piece to read if this post raised more questions than it answered.

One last practical note, because it is the item on this whole page that people most often skip. If a screen day ends with eyes that sting rather than ache, that is the tear film rather than the focusing muscle, and it responds to humidity, to screen height and to complete blinks far more than to anything swallowed. If it ends with a headache behind the brow and difficulty switching focus to something across the room, that is accommodation, and breaks and an accurate correction are the first two levers. Knowing which of the two you have is most of choosing what to do about it, and it costs nothing to pay attention for a week before buying anything at all.

References